Bank of Montreal’s TherapeuticsMD TXMD Stock Holding History

Bank of Montreal’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,100	Closed	-$143K	–	4989
2019 Q2	$143K	Buy	+1,100	New	+$197K	﹤0.01%	3118

Other funds holding TXMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank of Montreal's TXMD Position: Q2 2021 in Review

Bank of Montreal sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 200 shares — an estimated $13K sold.

Bank of Montreal first reported a position in TXMD in Q2 2014 and held it in 24 quarters. The position peaked at $1.32M in Q3 2019. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

Bank of Montreal reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
Bank of Montreal sold 200 TherapeuticsMD shares in Q2 2021, an estimated $13K.
Bank of Montreal first reported a position in TherapeuticsMD in Q2 2014 and held it in 24 quarters.
Bank of Montreal's TherapeuticsMD position peaked at $1.32M in Q3 2019.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.